Evidence map›Paper›PMID 22975993›Full record

ArticleKidney international2012

Adipose tissue-derived mesenchymal stem cells: a fat chance of curing kidney disease?

Fangming Lin

Registry-linked trialAbstract readComment
In one paragraph

Article in Kidney international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03939741 (Evaluation of Therapeutic Potential of Stromal Vascular Fraction), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03939741 phase1 / phase2unknown statusnot on this mapstarted 2019, after this paper: background citation

Evaluation of Therapeutic Potential of Stromal Vascular Fraction (Autologous Adipose Derived Mesenchymal Stem Cell) Based Treatment for Chronic Kidney Disease

TypeinterventionalSponsorBangladesh Laser & Cell Surgery Institute & HospitalRan2019 to 2025Enrolled31ConditionsChronic Kidney DiseasesArmsSVF Containg Autologous Non Expanded ADSC
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Effect of aging on stem cells.World journal of experimental medicine · 2017
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Fangming LinDepartment of Pediatrics, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA. fl2300@columbia.edu
Columbia University · US

Funding

STEM CELL THERAPY FOR ACUTE KIDNEY INJURYR01DK083411 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI LIN, FANGMING · 2009 to 2013
$1.6M
Use of Umbilical Core Blood derived HSC to Treat Acute Kidney InjuryRC1DK086886 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI LIN, FANGMING · 2009 to 2010
$606k
NIDDK NIH HHS R01 DK083411NIDDK NIH HHS RC1 DK086886
6 · The paper itself

Abstract

Many kidney diseases are associated with inflammation and altered immune response. Mesenchymal stem cells (MSCs) are known for their anti-inflammatory properties and immune modulation. Demonstration that the phenotype and immunosuppressive ability of adipose tissue-derived MSCs are not affected by human kidney disease or uremic serum might have clinical significance if autologous adipose tissue-derived MSCs can be tested to prove their long-term safety and efficacy in treating kidney disease.

Indexed as

Adipose TissueFemaleHumansKidney DiseasesMaleMesenchymal Stem Cells

Identifiers

PMID22975993
PMCPMC3445292
OpenAlexW2066995813

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.